☆ 4.7 Article

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

SCIENTIFIC REPORTS (2023)

Related references

Note: Only part of the references are listed.

Article Rheumatology

Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019

Anju Murayama et al.

Summary: The study found that there is a prevalent and substantial financial relationship between rheumatologists and pharmaceutical companies in Japan. From 2016 to 2019, 92 major pharmaceutical companies paid a total of $55,246,485 in personal payments for lecturing, writing, and consulting to 5038 board-certified rheumatologists. These payments were primarily concentrated on doctors in authoritative and influential positions.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2023)

Add to Collection

Article Otorhinolaryngology

Pharmaceutical Payments to Japanese Board-Certified Head and Neck Surgeons Between 2016 and 2019

Anju Murayama et al.

Summary: This study evaluated the financial relationship between Japanese head and neck surgeons and pharmaceutical companies from 2016 to 2019. The majority of the surgeons received personal payments, and there was an increasing trend in both the amount of payment per specialist and the prevalence of specialists with payments. The leading surgeons received significantly higher payments.

OTO OPEN (2023)

Add to Collection

Letter Infectious Diseases

Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan

Takanao Hashimoto et al.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Medicine, General & Internal

Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology

Ali Duarte-Garcia et al.

Summary: Payments from pharmaceutical companies to rheumatologists are associated with increased probability of prescribing and Medicare spending.

MAYO CLINIC PROCEEDINGS (2022)

Add to Collection

Article Urology & Nephrology

Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline

Anju Murayama et al.

Summary: This study examined the financial and nonfinancial conflicts of interest among authors of CKD guidelines in Japan and found that most of the recommendations were based on low-quality evidence tied to pharmaceutical companies. The study also revealed the lack of rigorous and transparent conflict of interest policies for nephrology guideline authors.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Article Otorhinolaryngology

Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis

Anju Murayama et al.

Summary: The study revealed significant financial relationships between allergic rhinitis CPG authors and pharmaceutical companies in Japan, particularly those marketing novel drugs. Additionally, authors had relatively high self-citation rates, indicating the need for more rigorous COI management strategies.

OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2022)

Add to Collection

Letter Oncology

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

Eiji Kusumi et al.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Environmental Sciences

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians

Anju Murayama et al.

Summary: This study assessed the awareness, influence on physician trustworthiness, and perception of financial conflicts of interest (FCOI) between pharmaceutical companies and healthcare domains among the Japanese cancer patient advocacy group members. Most respondents were aware of physician-Pharma interactions, considered them influential on clinical practice, and supported further regulation to protect patient-centered care.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Add to Collection

Letter Allergy

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic

Anju Murayama et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross-sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019

Sae Kamamoto et al.

Summary: This study assessed the personal payments made by pharmaceutical companies to pediatric hematologist-oncologists (PHOs) in Japan. The findings revealed that a majority of PHOs received personal payments from pharmaceutical companies between 2016 and 2019. The payments per PHO increased significantly during the study period, and leading PHOs received larger payments.

PEDIATRIC BLOOD & CANCER (2022)

Add to Collection

Article Environmental Sciences

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019

Anju Murayama et al.

Summary: This study retrospectively assessed the financial relationships between board-certified infectious disease specialists in Japan and pharmaceutical companies. The results showed substantial financial ties between these specialists and the companies, with higher-ranked specialists having stronger financial connections.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Add to Collection

Article Oncology

Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?

Kristin Wright et al.

Summary: A small number of medical oncologists receive very high payments from the pharmaceutical industry, and they hold major leadership roles within oncology. Further research is needed to explore the potential impact of these conflicts of interest on clinical practice and policy.

JCO ONCOLOGY PRACTICE (2022)

Add to Collection

Article Respiratory System

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019

Anju Murayama et al.

Summary: This study examined the financial relationships between respiratory specialists in Japan and pharmaceutical companies from 2016 to 2019. The findings revealed that a majority of respiratory specialists received increasing personal payments from pharmaceutical companies for lecturing, consulting, and writing. These financial relationships with pharmaceutical companies could potentially lead to conflicts of interest among respiratory physicians.

RESPIRATION (2022)

Add to Collection

Article Urology & Nephrology

Gender Disparities in Industry Payments to Urologists

Danielle Velez et al.

Summary: The analysis of the Open Payments Database reveals that, on average, female urologists earned half as much as male urologists in industry payments, with males earning more in all categories except for Ownership.

UROLOGY (2021)

Add to Collection

Article Oncology

Trends in Financial Relationships Between Industry and Radiation Oncologists Versus Other Physicians in the United States from 2014 to 2018

Deborah C. Marshall et al.

Summary: The study found that since the implementation of the Open Payments program, payments to radiation oncologists have significantly increased in both amount and frequency, while decreasing for medical oncologists and other hospital-based physicians. This indicates a trend of differentiation in industry payments among different groups of physicians.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Review Medicine, General & Internal

Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review

Aaron P. Mitchell et al.

Summary: The study found that financial payments from the drug industry to U.S. physicians are associated with physician prescribing practices, including increased prescribing of the paying company's drug, increased prescribing costs, and increased prescribing of branded drugs.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Letter Infectious Diseases

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies

Anju Murayama et al.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Oncology

Trends in Industry Payments to Medical Oncologists in the United States Since the Inception of the Open Payments Program, 2014 to 2019

Elizabeth S. Tarras et al.

Summary: From 2014 to 2019, a cohort of 15,585 US medical oncologists became less likely to receive industry payments, but the overall value of the payments increased. Over time, medical oncologists receiving lower-value payments (<$10,000) accepted smaller amounts and those receiving higher-value payments (>$10,000) accepted larger amounts. The trend in industry payments to medical oncologists since the inception of the Open Payments program highlights the limitations of transparency without accountability in policy making.

JAMA ONCOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States

Kosuke Inoue et al.

Summary: The study found that marketing payments related to PCSK9i received by physicians in 2016 were associated with an increase in PCSK9i prescriptions filled in 2017, especially among primary care physicians.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2021)

Add to Collection

Article Medicine, General & Internal

Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching

Kosuke Inoue et al.

Summary: The study found that industry payments to physicians were associated with higher prescription rates and costs of long-acting insulin. Physicians who received payments prescribed a greater number of claims, had higher costs for total claims, and higher costs per claim of long-acting insulin compared to those who did not receive payments.

PLOS MEDICINE (2021)

Add to Collection

Article Obstetrics & Gynecology

Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan

Kana Yamamoto et al.

Summary: Most Japanese authors of urology clinical practice guidelines received substantial payments from pharmaceutical companies, but inadequate transparency in disclosing financial conflicts may compromise the integrity of UCPG.

INTERNATIONAL UROGYNECOLOGY JOURNAL (2021)

Add to Collection

Article Rheumatology

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

Philip J. Mease et al.

Summary: The study demonstrated that brodalumab significantly improved symptoms and was well tolerated in patients with PsA compared to placebo.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Gender differences in industry payments among cardiologists

Inbar Raber et al.

AMERICAN HEART JOURNAL (2020)

Add to Collection

Editorial Material Orthopedics

Pharmaceutical Company Payments to the Professors of Orthopaedic Surgery Departments in Japan

Hiroaki Saito et al.

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2020)

Add to Collection

Article Health Care Sciences & Services

Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty

Mara A. G. Hollander et al.

JOURNAL OF GENERAL INTERNAL MEDICINE (2020)

Add to Collection

Article Urology & Nephrology

Gender Gap in Industry Relationships and Scholarly Impact Among Academic Urologists in the United States

Natalie M. Pace et al.

UROLOGY (2020)

Add to Collection

Article Health Care Sciences & Services

Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016

Akihiko Ozaki et al.

HEALTH POLICY (2020)

Add to Collection

Article Multidisciplinary Sciences

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan

Anju Murayama et al.

PLOS ONE (2020)

Add to Collection

Letter Medicine, General & Internal

Trends in Industry Payments to Physicians in the United States From 2014 to 2018

Deborah C. Marshall et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Oncology

Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology

Aaron P. Mitchell et al.

ONCOLOGIST (2019)

Add to Collection

Editorial Material Medicine, General & Internal

Pharmaceutical Company Payments to Executive Board Members of Professional Medical Associations in Japan

Hiroaki Saito et al.

JAMA INTERNAL MEDICINE (2019)

Add to Collection

Letter Medicine, General & Internal

Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians

Rishad Khan et al.

JAMA INTERNAL MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis

Akihiko Ozaki et al.

BMJ OPEN (2019)

Add to Collection

Article Medicine, General & Internal

Association between physician characteristics and payments from industry in 2015-2017: observational study

Kosuke Inoue et al.

BMJ OPEN (2019)

Add to Collection

Article Medicine, General & Internal

Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases

Bruno Goupil et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Editorial Material Medicine, General & Internal

COMMERCIAL INFLUENCE IN HEALTH: FROM TRANSPARENCY TO INDEPENDENCE Pathways to independence: towards producing and using trustworthy evidence

Ray Moynihan et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Article Medicine, General & Internal

Evaluation of Sex Distribution of Industry Payments Among Radiation Oncologists

Julius K. Weng et al.

JAMA NETWORK OPEN (2019)

Add to Collection

Article Medicine, General & Internal

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan

Hiroaki Saito et al.

JAMA NETWORK OPEN (2019)

Add to Collection

Letter Medicine, General & Internal

Types and Distributions of Biomedical Industry Payments to Men and Women Physicians by Specialty, 2015

Kathryn R. Tringale et al.

JAMA INTERNAL MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Types and Distribution of Payments From Industry to Physicians in 2015

Kathryn R. Tringale et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Add to Collection

Article Medicine, General & Internal

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim A. Papp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Otorhinolaryngology

Association of Gender With Financial Relationships Between Industry and Academic Otolaryngologists

Jean Anderson Eloy et al.

JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2017)

Add to Collection

Article Medicine, General & Internal

Disclosure of Industry Payments to Physicians: An Epidemiologic Analysis of Early Data From the Open Payments Program

Deborah C. Marshall et al.

MAYO CLINIC PROCEEDINGS (2016)

Add to Collection

Article Dermatology

Exploring the Industry-Dermatologist Financial Relationship Insight From the Open Payment Data

Hao Feng et al.

JAMA DERMATOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials

Richard G. Langley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Professional Medical Associations and Their Relationships With Industry A Proposal for Controlling Conflict of Interest

David J. Rothman et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)

Add to Collection

Editorial Material Medicine, General & Internal

Key opinion leaders - Independent experts or drug representatives in disguise?

Ray Moynihan

BRITISH MEDICAL JOURNAL (2008)

Add to Collection

Article Dermatology

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis

D. Revicki et al.

BRITISH JOURNAL OF DERMATOLOGY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.